ClinicalTrials.gg
Active, not recruitingNCT04098211Updated Apr 8, 2026

Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency Patients

An observational study in Neuronal Ceroid-Lipofuscinoses, Neuronal Ceroid Lipofuscinosis CLN2 and Spinocerebellar Ataxia, Autosomal Recessive 7, sponsored by Children's Hospital of Orange County. Active, not recruiting at 1 site in United States. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Children's Hospital of Orange County · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
5
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Neuronal Ceroid-Lipofuscinoses with a site in United States — 10 open to participants now, 18 under way, none of them phase 3. Neuronal Ceroid-Lipofuscinoses · United States.

Enrollment
18th of 18
5 · median 65
Started
2019
the only one that year
Observational
18 of 38
8 open now
Primary completion
2026-12
later than 2 of 17 live
Registered
27th of 38
by date
Lead sponsor
1 of 38
Children's Hospital of Orange County

Among the 38 studies in Neuronal Ceroid-Lipofuscinoses with a site in United States, this one is the 18th largest by enrollment of the 18 observational ones that give a count, is the only one that started in 2019, is one of 18 observational ones, reaches primary completion later than 2 of the 17 other live ones, and was the 27th registered.

Neuronal Ceroid-Lipofuscinoses

49 studies on the registry are indexed under Neuronal Ceroid-Lipofuscinoses; 13 are open to participants now.

Browse Neuronal Ceroid-Lipofuscinoses studies →

Open to participants now

10 of the 38 studies in Neuronal Ceroid-Lipofuscinoses with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Neuronal Ceroid-Lipofuscinoses studies recruiting now, 7 (64%) set no upper age limit and 2 (18%) stop at 75 or younger; 10 take children under 18; 2 take healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Neuronal Ceroid-Lipofuscinoses with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to gather information on the possible symptoms that patients with atypical neuronal ceroid lipofuscinosis type 2 (also known as aTPP1 or atypical tripeptidyl peptidase deficiency) have and how they change over time.

Read the detailed description

This study aims characterize the natural history of atypical TPP1 deficiency patients via longitudinal multidisciplinary assessments.

Multifaceted clinical, laboratory, imaging, and diagnostic assessments will be performed at regular intervals upon enrolled aTPP1 deficiency patients, collated, and analyzed over a three-year longitudinal period.

03

Conditions studied

  • Neuronal Ceroid-Lipofuscinoses
  • Neuronal Ceroid Lipofuscinosis CLN2
  • Spinocerebellar Ataxia, Autosomal Recessive 7

Keywords

  • Neuronal Ceroid Lipofuscinosis
  • Atypical CLN2 Disease
  • Natural History
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any patient with documented TPP1 enzymatic deficiency or TPP1 sequence variants with onset of first symptom after 4 years of age

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any patient with documented TPP1 enzymatic deficiency or TPP1 sequence variants
  • Onset of first symptom after 4 years of age
  • Parental provision of ; child provision of assent (if necessary)

Exclusion criteria

Exclusion Criteria:

  • Any patient with "Classical" TPP1 deficiency (onset of first symptom prior to 4 years of age)
  • Investigator assessment that patient is not suitable candidate to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
5 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. CLN2 Disease Severity Scoring

    Modified Hamburg Rating Scale. The rating scale consists of two domains (motor function, language). Within each domain, a score from 0 to 3 is assigned and overall scores are calculated by summing the domain scores for final rating of 0 (severely impaired) to 6 (normal).

    Time frame: At baseline and every 3 months afterwards, up to 3 years

  2. Electroretinogram (ERG)

    Standard ERG will be performed to measure function of cones and rods of the inner and outer photoreceptor layers which amplitudes are typically decreased in classical TPP1 deficiency.

    Time frame: At baseline and every 6 months afterwards, up to 3 years

  3. Optical Coherence Tomography (OCT)

    OCT is non-invasive, quantitative measurement of inner and outer photoreceptor layer thicknesses.

    Time frame: At baseline and every 6 months afterwards, up to 3 years

  4. Gait Assessment

    Gait assessment is acquired utilizing infrared sensors applied to participant's clothing and will include collection of walking speed, cadence, swing phase, stride length and time, walking base width, stance phase, and double limb support phase.

    Time frame: At baseline and every 6 months afterwards, up to 3 years

  5. Brain Magnetic Resonance Imaging (MRI)

    Pre/post-contrast images will be acquired to perform volumetric studies and white matter assessment.

    Time frame: At baseline and every 12 months afterwards, up to 3 years

  6. Electroencephalography (EEG)

    EEG will be obtained and analyzed for changes that may be distinctive for TPP1 deficiency. Evaluation of background activity, mild/moderate/severe slowing for age.

    Time frame: At baseline and every 12 months afterwards, up to 3 years

  7. Electroencephalography (EEG)

    EEG will be obtained and analyzed for changes that may be distinctive for TPP1 deficiency. Interictal discharges: location, focal/generalized, discharge burden.

    Time frame: At baseline and every 12 months afterwards, up to 3 years

  8. Electroencephalography (EEG)

    Seizures.

    Time frame: At baseline and every 12 months afterwards, up to 3 years

  9. Electroencephalography (EEG)

    Photoparoxysmal response: present/absent

    Time frame: At baseline and every 12 months afterwards, up to 3 years

  10. Cognitive Assessment, Wechsler Intelligence Scale for Children version 4 (WISC-IV)

    WISC-IV will generate a full scale of intelligence quotient and five primary index scores: Verbal Comprehension, Visual Spatial, Fluid Reasoning, Working Memory, and Processing Speed. The WAIS-IV is scored by summing the raw scores for each subtest; each raw subtest score is then converted to a scaled scored. They are then combined to create a Full Scale IQ Index score. Test takers will also be given a score on the General Ability Index (GAI).

    Time frame: At baseline and every 12 months afterwards, up to 3 years

  11. CSF Testing

    Standard laboratory testing and biobanking / storage of remaining CSF (via Ommaya if on enzyme replacement; via lumbar puncture if not on enzyme replacement)

    Time frame: At baseline and every 3 months afterwards, up to 3 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2019 (actual). Primary completion is estimated for Dec 2026, 85 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2019
First posted
Sep 23, 2019
StartActual
Nov 1, 2019
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04098211
Lead sponsor
Children's Hospital of Orange County
Responsible party
Sponsor
First posted
Sep 23, 2019
Start date
Nov 1, 2019
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion